GCSF Adjunct Therapy for Biliary Atresia

Completed · Early Phase 1

Conditions studied: Biliary Atresia

In brief

The Investigators propose to test the hypothesis that GCSF therapy enhances the clinical outcome of Kasai operated Biliary Atresia (BA) patients. In this study, Investigators will conduct a dose determination for GCSF use in post Kasai subjects to support a future phase 2 efficacy study. The first 3 post Kasai BA subjects with liver biopsy-confirmed BA will be given 5 ug/kg/d of GCSF in 3 daily subcutaneous doses starting on post Kasai day 3. A second group of 3 subjects will be assigned to the 10 ug/Kg/d dose after the 5ug/kg/d dose has been proven to be safe. The levels of circulating hematopoietic stem cells and a 1-month safety profile will be analyzed.

Key facts

Study ID

NCT03395028

Run by

Holterman, Ai-Xuan, M.D.

People needed

6

Starts

2018-01-15

Expected to finish

2020-01-31

Last updated by the study team

2020-02-17

Who can join

Age: 0 and older, up to 0. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Completed the preliminary work up for cholestasis with suspected or inconclusive diagnosis of BA
• Gestational Age > 36wks
• Weight > 2 Kg
• Age >-2 weeks-<180 days at diagnosis
• Serum Direct Bilirubin > 2 mg/dL GGT > 100 U/L
• Kasai operated patients for Type 3 or 4 anatomy of BA
• Cholangiogram/porta hepatis findings diagnostic of BA
• Liver biopsy supporting BA diagnosis

You may not qualify if…

• Having access to liver transplantation for immediate Kasai failure
• Prior Kasai patients
• Major cardiac, renal, CNS malformations with poor prognosis
• Intracranial hemorrhage
• History of recent TPN use within the last 2 weeks of surgery
• GI tract obstruction
• Laparoscopic Kasai repair

Where it is running

• Children's National Medical Center — Washington D.C., District of Columbia, United States
• National Childrens Hospital — Hanoi, Vietnam

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.